TABLE 1

Characteristics of 8 Charles River CD IGS Rats

Animal	Experiment	Weight (g)	Intervention	Route	Outcome
I	SM	480	Insulin, 0.0083 IU/kg	Tail vein	¹⁸F-FDG uptake
II	SM	590	Insulin, 0.0041 IU/kg	Tail vein	¹⁸F-FDG uptake
	SF	590	Insulin, 3.39 IU/kg	Tail vein	¹⁸F-FDG uptake
	SF	573	Insulin, 20.94 IU/kg	Tail vein	¹⁸F-FDG uptake
III	Sham	622	No insulin	Not applicable	¹⁸F-FDG uptake
IV	SF	495	Insulin, 48.48 IU/kg	Tail vein	¹⁸F-FDG uptake
V	IAM SM (Sys + CL)	267	Insulin, 0.38 IU/kg	Left femoral artery	Insulin and glucose plasma levels
VI	IAM SM (Sys + CL)	294	Insulin, 0.34 IU/kg	Left femoral artery	¹⁸F-FDG uptake
VII	IAM SM (Sys + CL)	289	Insulin, 0.346 IU/kg	Left femoral artery	¹⁸F-FDG uptake
VIII	Sham Sys + IL	300	Saline	Left femoral artery	¹⁸F-FDG uptake

Rats II, V, VI, VII, and VIII had multiple experiments either over different days (rat II) or contemporaneously (rats V, VI, VII, and VIII) for a total of 17 datasets composed of 14 experimental sets of imaging data (¹⁸F-FDG) and 3 sets of chemical data (insulin and glucose plasma levels). Contemporaneous data refer to IAM data that were obtained together with systemic/contralateral microdose control data, at same time in same animal.
SM (8 experiments) = systemic microdose (including systemic microdose [Sys] and contralateral microdose [CL] effects after IAM); SF (3 experiments) = systemic full-dose comparator; Sham (3 experiments) = systemic exposure after no insulin or saline interventions (animal VIII had 2 datasets: systemic [Sys] and ipsilateral [IL]); IAM (3 experiments) = intraarterial microdosing intervention and ipsilateral (target) effects.